LPX EWS/FL1 T1 / Gradalis - LARVOL DELTA

Pbi-shRNA™ EWS/FLI1 Type 1 LPX in Subjects With Advanced Ewing's Sarcoma (clinicaltrials.gov) - P1 | N=7 | Completed | Sponsor: Gradalis, Inc. | N=28 ➔ 7

Enrollment change • Metastases • Ewing Sarcoma • Oncology • Rare Diseases • Sarcoma • Solid Tumor

Pbi-shRNA™ EWS/FLI1 Type 1 LPX in Subjects With Advanced Ewing's Sarcoma (clinicaltrials.gov) - P1 | N=28 | Completed | Sponsor: Gradalis, Inc. | Active, not recruiting ➔ Completed | Trial completion date: Dec 2023 ➔ Mar 2023 | Trial primary completion date: Jun 2023 ➔ Mar 2023

Trial completion • Trial completion date • Trial primary completion date • Ewing Sarcoma • Oncology • Rare Diseases • Sarcoma • Solid Tumor • EWSR1 • FLI1

Pbi-shRNA™ EWS/FLI1 Type 1 LPX in Subjects With Advanced Ewing's Sarcoma (clinicaltrials.gov) - P1 | N=28 | Active, not recruiting | Sponsor: Gradalis, Inc. | Trial primary completion date: Jan 2023 ➔ Jun 2023

Metastases • Trial primary completion date • Ewing Sarcoma • Oncology • Rare Diseases • Sarcoma • Solid Tumor • EWSR1 • FLI1

Pbi-shRNA™ EWS/FLI1 Type 1 LPX in Subjects With Advanced Ewing's Sarcoma (clinicaltrials.gov) - P1 | N=28 | Active, not recruiting | Sponsor: Gradalis, Inc. | Trial completion date: Dec 2022 ➔ Dec 2023 | Trial primary completion date: Jan 2022 ➔ Jan 2023

Trial completion date • Trial primary completion date • Ewing Sarcoma • Oncology • Rare Diseases • Sarcoma • Solid Tumor • EWSR1 • FLI1